155 related articles for article (PubMed ID: 37330972)
1. Real-World Biomarker Test Utilization and Subsequent Treatment in Patients with Early-Stage Non-small Cell Lung Cancer in the United States, 2011-2021.
Yan JT; Jin Y; Lo E; Chen Y; Hanlon Newell AE; Kong Y; Inge LJ
Oncol Ther; 2023 Sep; 11(3):343-360. PubMed ID: 37330972
[TBL] [Abstract][Full Text] [Related]
2. Real-world patterns of biomarker testing and targeted therapy in de novo metastatic non-small cell lung cancer patients in the US oncology network.
Nadler E; Vasudevan A; Wang Y; Ogale S
Cancer Treat Res Commun; 2022; 31():100522. PubMed ID: 35189530
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data.
Dudnik E; Moskovitz M; Rottenberg Y; Lobachov A; Mandelboim R; Shochat T; Urban D; Wollner M; Nechushtan H; Rotem O; Zer A; Daher S; Bar J;
Oncoimmunology; 2021 Jan; 10(1):1865653. PubMed ID: 33552685
[TBL] [Abstract][Full Text] [Related]
4. Real-world biomarker testing rate and positivity rate in NSCLC in Spain: Prospective Central Lung Cancer Biomarker Testing Registry (LungPath) from the Spanish Society of Pathology (SEAP).
Salas C; Martín-López J; Martínez-Pozo A; Hernández-Iglesias T; Carcedo D; Ruiz de Alda L; García JF; Rojo F
J Clin Pathol; 2022 Mar; 75(3):193-200. PubMed ID: 33722840
[TBL] [Abstract][Full Text] [Related]
5. Biomarker testing for personalized, first-line therapy in advanced nonsquamous non-small cell lung cancer patients in the real world setting in Japan: a retrospective, multicenter, observational study (the BRAVE study).
Shimizu J; Masago K; Saito H; Nishino K; Kurata T; Itoh Y; Yoshimura Y; Yabuki Y; Dosaka-Akita H
Ther Adv Med Oncol; 2020; 12():1758835920904522. PubMed ID: 32127924
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1.
Lee J; Park CK; Yoon HK; Sa YJ; Woo IS; Kim HR; Kim SY; Kim TJ
Thorac Cancer; 2019 Jan; 10(1):103-110. PubMed ID: 30475455
[TBL] [Abstract][Full Text] [Related]
7. Biomarker testing strategies in non-small cell lung cancer in the real-world setting: analysis of methods in the Prospective Central Lung Cancer Biomarker Registry (LungPath) from the Spanish Society of Pathology (SEAP).
Martín-López J; Rojo F; Martínez-Pozo A; Hernández-Iglesias T; Carcedo D; de Alda LR; García JF; Salas C
J Clin Pathol; 2023 May; 76(5):327-332. PubMed ID: 34903610
[TBL] [Abstract][Full Text] [Related]
8. Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network.
Robert NJ; Espirito JL; Chen L; Nwokeji E; Karhade M; Evangelist M; Spira A; Neubauer M; Bullock S; Walberg J; Cheng SK; Coleman RL
Lung Cancer; 2022 Apr; 166():197-204. PubMed ID: 35313244
[TBL] [Abstract][Full Text] [Related]
9. Biopsy Procedures and Molecular Testing Utilization and Related Costs in Patients with Metastatic Lung Cancer.
Shinde R; Cao X; Kothari S
J Manag Care Spec Pharm; 2016 Oct; 22(10):1194-203. PubMed ID: 27668568
[TBL] [Abstract][Full Text] [Related]
10. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.
Bahnassy AA; Ismail H; Mohanad M; El-Bastawisy A; Yousef HF
J Egypt Natl Canc Inst; 2022 May; 34(1):23. PubMed ID: 35644823
[TBL] [Abstract][Full Text] [Related]
11. Aberrant status and clinicopathologic characteristic associations of 11 target genes in 1,321 Chinese patients with lung adenocarcinoma.
Zhao M; Zhan C; Li M; Yang X; Yang X; Zhang Y; Lin M; Xia Y; Feng M; Wang Q
J Thorac Dis; 2018 Jan; 10(1):398-407. PubMed ID: 29600072
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of lung cancer biomarkers profile for the decision of targeted therapy in EBUS-TBNA cytological samples.
Gürün Kaya A; Çiledağ A; Erol S; Öz M; Doğan Mülazımoğlu D; Işık Ö; Özakıncı H; Çiftçi F; Şen E; Ceyhan K; Kaya A; Karnak D; Çelik G; İsmail S
Scott Med J; 2022 Feb; 67(1):18-27. PubMed ID: 35147461
[TBL] [Abstract][Full Text] [Related]
13. Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy.
Faber E; Grosu H; Sabir S; San Lucas FA; Barkoh BA; Bassett RL; Luthra R; Stewart J; Roy-Chowdhuri S
J Clin Pathol; 2022 Sep; 75(9):612-619. PubMed ID: 33952592
[TBL] [Abstract][Full Text] [Related]
14. Comparison of PD-L1, EGFR, ALK, and ROS1 Status Between Surgical Samples and Cytological Samples in Non-Small Cell Lung Carcinoma.
Ekin Z; Nart D; Savaş P; Veral A
Balkan Med J; 2021 Sep; 38(5):287-295. PubMed ID: 34558414
[TBL] [Abstract][Full Text] [Related]
15. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma.
Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB
J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537
[TBL] [Abstract][Full Text] [Related]
16. Real-World Clinical Impact of Immune Checkpoint Inhibitors in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer After Platinum Chemotherapy.
Schwartzberg L; Korytowsky B; Penrod JR; Zhang Y; Le TK; Batenchuk C; Krug L
Clin Lung Cancer; 2019 Jul; 20(4):287-296.e4. PubMed ID: 31130450
[TBL] [Abstract][Full Text] [Related]
17. Somatic mutations and immune checkpoint biomarkers.
Parris BA; Shaw E; Pang B; Soong R; Fong K; Soo RA
Respirology; 2019 Mar; 24(3):215-226. PubMed ID: 30636374
[TBL] [Abstract][Full Text] [Related]
18. Molecular profiling of advanced non-small cell lung cancer in the era of immunotherapy approach: a multicenter Italian observational prospective study of biomarker screening in daily clinical practice.
Vavala T; Malapelle U; Veggiani C; Ludovini V; Papotti M; Leone A; Graziano P; Minari R; Bono F; Sapino A; Manotti L; Troncone G; Pisapia P; Girlando S; Buffoni L; Righi L; Colantonio I; Bertetto O; Novello S
J Clin Pathol; 2022 Apr; 75(4):234-240. PubMed ID: 33509945
[TBL] [Abstract][Full Text] [Related]
19. Correlation between Programmed Death Ligand-1(PD-L1) Expression and Driver Gene Mutations in Non-Small Cell Lung Carcinoma- Adenocarcinoma Phenotype.
Pandey RK; Shukla S; Husain N; Islam MH; Hadi R; Kant Tripathi S; Singhal A
Asian Pac J Cancer Prev; 2022 Jan; 23(1):131-142. PubMed ID: 35092381
[TBL] [Abstract][Full Text] [Related]
20.
Overbeck TR; Reiffert A; Schmitz K; Rittmeyer A; Körber W; Hugo S; Schnalke J; Lukat L; Hugo T; Hinterthaner M; Reuter-Jessen K; Schildhaus HU
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
